Sec Form 4 Filing - AGUIAR ERIC @ Biohaven Pharmaceutical Holding Co Ltd. - 2020-01-08

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person AGUIAR ERIC 2. Issuer Name and Ticker or Trading Symbol Biohaven Pharmaceutical Holding Co Ltd. [ BHVN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O AISLING CAPITAL LLC, 888 SEVENTH AVENUE, 12TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 01/08/2020 (Street) NEW YORK, NY10106 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 01/09/2020 M 30,000 A $ 9.29 30,000 D Common Shares 01/09/2020 S 30,000 D $ 56.39 0 D Common Shares 01/08/2020 M 1,250 A $ 55.91 1,250 I By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 9.29 01/09/2020 M 30,000 ( 1 ) 12/14/2026 Common Shares 30,000 $ 0 0 D Restricted Share Unit Award ( 2 ) 01/08/2020 A 5,000 ( 3 ) ( 4 ) Common Stock 5,000 $ 0 5,000 I By Spouse ( 5 ) Restricted Share Unit Award ( 2 ) 01/08/2020 M 1,250 ( 3 ) ( 4 ) Common Stock 1,250 $ 0 3,750 I By Spouse ( 5 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other AGUIAR ERIC C/O AISLING CAPITAL LLC 888 SEVENTH AVENUE, 12TH FLOOR NEW YORK, NY10106 X Signatures /s/ Jim Engelhart, Attorney-in-fact 01/10/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The option, representing a right to purchase a total of 30,000 shares was granted on December 15, 2016, vested in four equal installments on December 15, 2016, 2017, 2018 and 2019, subject to the optionholder's continuous service with the Issuer at each vesting date. ( 2 )Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. ( 3 )The reporting person was granted 5,000 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023 subject to the reporting person's continued service with the issuer at each vesting date. ( 4 )Not applicable. ( 5 )This restricted stock unit is held by the reporting person's spouse as an employee of the issuer.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.